Inhibikase Therapeutics, Inc. announced that it will receive $7,999,999 in funding on May 20, 2024. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +12.77% | -2.45% | +25.20% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.20% | 11.47M | |
+38.66% | 52.85B | |
+35.74% | 38.24B | |
-7.81% | 38.87B | |
-10.77% | 26.79B | |
+11.77% | 26.16B | |
-17.82% | 19.9B | |
+35.09% | 13.18B | |
+29.17% | 12.24B | |
-3.05% | 11.79B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. announced that it expects to receive $7.999999 million in funding